Mark M. Awad

Mark M. Awad, MD, PhD is Clinical Director of the Lowe Center for Thoracic Oncology at Dana-Farber Cancer Institute and Associate Professor of Medicine at Harvard Medical School. He is a leading clinical scientist at the intersection of KRAS-targeted therapy, thoracic immunotherapy, and rare thoracic malignancies. Dr. Awad has been one of the most prominent investigators in the development of KRAS G12C inhibitors in non-small cell lung cancer, serving as a key contributor to the CodeBreaK program: his work in CodeBreaK 100 helped establish sotorasib's clinical profile, and he was among the senior investigators for CodeBreaK 200—the randomized phase III trial that demonstrated sotorasib superior objective response rate and non-inferior PFS compared to docetaxel in previously treated KRAS G12C-mutant advanced NSCLC, leading to full FDA approval. He has also contributed to understanding KRAS co-mutation biology and resistance mechanisms to KRAS G12C inhibitors including adaptive RTK upregulation and RAS pathway reactivation, informing combination strategies with SHP2, MEK, and EGFR inhibitors. In parallel, Dr. Awad has built an internationally recognized mesothelioma research program at Dana-Farber, contributing to trials of immunotherapy combinations (nivolumab + ipilimumab; CheckMate 743) and novel targeted approaches in this difficult disease. He has authored more than 200 peer-reviewed publications.